NEW STUDY TO UNDERSTAND NET PATIENT
EXPERIENCE WITH TREATMENT
We’re excited to share with you a new study for patients with neuroendocrine tumors (NETs) who have switched from monthly Sandostatin LAR® (octreotide) to Somatuline® Depot (lanreotide) injections within the past 12 months. If you are 21 years or older and live in the United States, we invite you to see if you are eligible to participate. Please check this out today because there are a limited number of individuals who can participate in the study.
The goals of the study are to explore the differences between the 2 somatostatin analog (SSA) injections, to understand preferences for SSA treatment among NET patients, and to describe the reasons for the change from Sandostatin LAR® (octreotide) to Somatuline® Depot (lanreotide). By participating in the study you can help raise awareness about treatment options for NET patients and their experience with SSA treatment.
If you are interested in participating, please follow the link below to take a brief (5-10 minute) screening survey to determine if you are eligible for the study. If you qualify based on the screening survey, you will be scheduled for a telephone interview with our research partner so we can learn more about your experiences with NETs and their treatment. The interview will be scheduled for a time that is convenient for you, and should take about one hour.
Immediately upon completion of the interview, in appreciation for your time, a Visa gift card in the amount of $100 will be mailed to you.